Traders sold shares of Biogen Inc. (NASDAQ:BIIB) on strength during trading on Monday. $276.87 million flowed into the stock on the tick-up and $295.26 million flowed out of the stock on the tick-down, for a money net flow of $18.39 million out of the stock. Of all equities tracked, Biogen had the 0th highest net out-flow for the day. Biogen traded up $11.90 for the day and closed at $301.83

A number of brokerages have recently issued reports on BIIB. Jefferies Group restated a “buy” rating on shares of Biogen in a report on Thursday, June 30th. Citigroup Inc. restated a “buy” rating and set a $345.00 price objective on shares of Biogen in a report on Monday, April 11th. Leerink Swann restated a “market perform” rating and set a $319.00 price objective on shares of Biogen in a report on Wednesday, June 1st. Robert W. Baird restated a “hold” rating on shares of Biogen in a report on Monday, May 16th. Finally, Piper Jaffray Cos. restated a “hold” rating and set a $293.00 price objective on shares of Biogen in a report on Tuesday, June 7th. Nine research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $327.25.

The company has a market capitalization of $66.14 billion and a price-to-earnings ratio of 17.63. The firm’s 50 day moving average price is $254.65 and its 200-day moving average price is $262.97.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Thursday, July 21st. The biotechnology company reported $5.21 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.69 by $0.52. During the same period last year, the business posted $4.22 earnings per share. The business earned $2.89 billion during the quarter, compared to the consensus estimate of $2.79 billion. The firm’s quarterly revenue was up 11.7% on a year-over-year basis. Analysts anticipate that Biogen Inc. will post $20.14 EPS for the current fiscal year.

In other Biogen news, CEO George A. Scangos sold 157 shares of the firm’s stock in a transaction on Wednesday, May 25th. The shares were sold at an average price of $280.00, for a total value of $43,960.00. Following the completion of the transaction, the chief executive officer now directly owns 59,633 shares of the company’s stock, valued at approximately $16,697,240. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO George A. Scangos sold 3,855 shares of the firm’s stock in a transaction on Wednesday, June 1st. The shares were sold at an average price of $289.74, for a total transaction of $1,116,947.70. Following the completion of the transaction, the chief executive officer now directly owns 56,265 shares of the company’s stock, valued at $16,302,221.10. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have recently made changes to their positions in BIIB. BlackRock Investment Management LLC increased its position in shares of Biogen by 0.8% in the fourth quarter. BlackRock Investment Management LLC now owns 1,097,747 shares of the biotechnology company’s stock valued at $336,295,000 after buying an additional 8,756 shares during the last quarter. Westfield Capital Management Co. LP increased its position in shares of Biogen by 74,344.5% in the fourth quarter. Westfield Capital Management Co. LP now owns 513,667 shares of the biotechnology company’s stock valued at $157,362,000 after buying an additional 512,977 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Biogen by 5.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 418,648 shares of the biotechnology company’s stock valued at $128,259,000 after buying an additional 19,889 shares during the last quarter. State of Tennessee Treasury Department increased its position in shares of Biogen by 211.4% in the fourth quarter. State of Tennessee Treasury Department now owns 383,602 shares of the biotechnology company’s stock valued at $117,516,000 after buying an additional 260,412 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D increased its position in shares of Biogen by 6.5% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 328,485 shares of the biotechnology company’s stock valued at $100,631,000 after buying an additional 20,000 shares during the last quarter.

Biogen Inc, formerly Biogen Idec Inc, is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.